Hematologist
CION Cancer Clinics
Ruxolitinib and second-line GVHD treatment | CION Cancer Clinics
If steroids do not control GVHD, or it flares each time the dose is lowered, the usual next step is a second-line medicine. Ruxolitinib, a daily tablet that calms donor immune cells, is now a standard choice for both acute and chronic GVHD. It needs regular blood tests because it can lower counts and raise infection risk. This page explains how it works, the other options and what it cannot tell you. At CION Cancer Clinics, our haematology team assesses whether a transplant or CAR-T fits your situation and coordinates care with qualified centres.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What happens when steroids do not control GVHD?
- Refractory, dependent or intolerant: what is the difference?
- What second-line treatments might your team consider?
- How is ruxolitinib started and monitored?
- What side effects can ruxolitinib cause?
- What do families often believe about second-line GVHD treatment?
- What do the terms in your treatment notes mean?
- Common questions about ruxolitinib for GVHD
The short answer
What happens when steroids do not control GVHD?
When steroids do not control GVHD, doctors call it steroid-refractory GVHD, and the usual next step is a second-line medicine. Ruxolitinib, a tablet that blocks signals the donor immune cells use to stay active, is now a standard choice for both acute and chronic GVHD in this situation.
This is common, and it is not the end of the options
A good share of people with GVHD need more than steroids. Hearing the word refractory can feel frightening. It means only that the first medicine was not enough on its own. Your team has several options after it, and steroids are usually continued alongside while the new medicine takes effect.
How ruxolitinib works, in plain words
Immune cells pass messages inside themselves using proteins called JAK1 and JAK2. Ruxolitinib is a JAK inhibitor, meaning it blocks those messages. The donor cells become less active, so the attack on your skin, gut, liver or other organs eases. Because it also quiets the parts of the immune system that fight infection, careful monitoring is part of the treatment.
Who it may not suit
Ruxolitinib can lower blood counts, so it needs extra care when platelets or white cells are already very low. It may also be unsuitable during an active serious infection, or alongside some other medicines. Your team weighs these before starting.
What to ask your transplant team
Ask which organs they are treating, how they will judge whether the medicine is working, and how often you need blood tests. Ask what to do if you get a fever at night, and who to call. Ask what the next option would be if this one does not help, so you are not caught off guard.
Your transplant team decides whether to start ruxolitinib and at what dose. Never start, stop or change it on your own.The words doctors use
Refractory, dependent or intolerant: what is the difference?
What the doctor may write
What it means for you
Steroid-refractory
GVHD got worse, or did not improve enough, on steroids
Steroid-dependent
GVHD settles on steroids but flares each time the dose is lowered
Steroid-intolerant
Steroid side effects are too harmful to continue at the needed dose
Second-line treatment
A medicine added after steroids, usually while steroids continue
Not sure whether this applies to you?
Ask an oncologistThe options
What second-line treatments might your team consider?
The choice depends on whether GVHD is acute or chronic, which organs are affected, your blood counts and what your transplant centre can offer.
Ruxolitinib
A daily tablet used for steroid-refractory acute and chronic GVHD. Large studies found it helped more people than other available treatments did.
Extracorporeal photopheresis
Your blood is drawn through a machine, the white cells are treated with a light-activated medicine, and returned. It is given in repeated sessions at specialist centres.
Needs good vein access and regular travel.Belumosudil
A tablet used for chronic GVHD after other treatments have not worked. It is not used for acute GVHD.
Other immune-calming medicines
Depending on the situation, your team may use other medicines or a clinical trial.
Names you may hear
- Mycophenolate
- Sirolimus
- Ibrutinib, for chronic GVHD
On treatment
How is ruxolitinib started and monitored?
Checks before starting
Blood counts, liver and kidney tests, and a review of your current medicines and any infection. Some medicines raise ruxolitinib levels and need adjusting.
Regular blood tests
Counts are checked often in the early weeks, because platelets and haemoglobin can fall. Your team may adjust or pause the dose based on results.
Watching for infection
Viral tests, such as for CMV, and preventive medicines continue. Any fever is reported the same day.
Reviewing the response
The team compares the rash, stools, liver tests or breathing with before. If GVHD improves, steroids are slowly reduced first.
Reducing it later
Once GVHD has stayed quiet for some time, your team may lower ruxolitinib gradually, watching for any flare at each step.
Side effects
What side effects can ruxolitinib cause?
The most common side effects are lower blood counts and infections. Many people take it without major problems, but the checks matter because the effects often show on blood tests before you feel them.
Blood counts
A low platelet count raises the chance of bruising and bleeding. A low haemoglobin causes tiredness and breathlessness. A low white cell count raises the chance of infection. Report nosebleeds, bleeding gums, black stools or new bruises.
Infections
Viral infections such as CMV, and shingles, can become active again. Chest and urine infections are also more likely. Fever, cough, burning urine or a painful blistering rash need a call to your team the same day.
Other effects
Raised liver tests, raised cholesterol, swelling of the legs and dizziness can occur. If ruxolitinib is stopped, it is usually reduced gradually on your team's advice, because stopping suddenly can let symptoms return.
Day to day on the tablets
Most people take ruxolitinib at home and carry on with daily life between clinic visits. Take it at the same times each day, keep a written list of every medicine, and never borrow or share tablets. Keep a thermometer at home. If you feel much more tired or breathless than usual, ask for a blood count check rather than waiting for the next review.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
What do families often believe about second-line GVHD treatment?
"If steroids failed, nothing else will work."
Steroid-refractory GVHD responds to second-line treatment in many people. Some need to try more than one option before GVHD settles.
"Ruxolitinib is a chemotherapy, so it will cause hair loss."
It is not chemotherapy in the usual sense. It calms immune signalling. Hair loss is not a typical effect, though blood counts do need watching.
"A cheaper version from a local shop is the same."
Only take medicine supplied on your team's prescription from a reliable pharmacy. Tell the team if cost is a problem, because they may know of support schemes.
"Now that ruxolitinib has started, the steroids can stop."
Steroids are reduced slowly on a plan once GVHD improves. Stopping them early can cause a flare and serious weakness.
On your notes
What do the terms in your treatment notes mean?
- JAK inhibitor
- A medicine that blocks JAK proteins inside immune cells. Ruxolitinib is one.
- Overall response
- GVHD improved, either partly or completely, in the organs being treated.
- Flare
- GVHD signs coming back or worsening, often as medicines are reduced.
- CMV reactivation
- A common virus that lies quiet in the body becoming active again when immunity is low.
- ECP
- Short for extracorporeal photopheresis, the light-based blood treatment described above.
Questions we are asked
Common questions about ruxolitinib for GVHD
How soon does ruxolitinib start working?
Some people notice improvement within weeks, while chronic GVHD often takes longer to respond. Your team will judge the response at planned reviews rather than day by day. Keep a simple diary of the rash, stools, appetite and energy, because it helps them see change over time.
Is ruxolitinib available in India?
Yes. Ruxolitinib is available in India, including generic versions, on a specialist's prescription. Cost varies with the version and dose. Ask your team about Aarogyasri, CGHS, ECHS, EHS, PM-JAY or insurance cover, since scheme rules change and your own entitlement needs checking.
Can I take ruxolitinib with my other transplant medicines?
Usually yes, but some medicines change its level in the blood, including certain antifungals and antibiotics. Your team checks for these and may adjust doses. Tell every doctor who treats you, and your pharmacist, that you take ruxolitinib.
Will ruxolitinib make the leukaemia come back?
Any medicine that calms the immune system could in theory weaken the donor cells' fight against the original disease. Your team aims to control GVHD with the least immune calming needed. They will also watch for signs of relapse during follow-up and explain your own situation.
How long will I need to take it?
It varies. Some people take it for months, others longer, especially with chronic GVHD. Once GVHD is controlled and steroids are reduced, your team may slowly lower ruxolitinib too. It is not stopped suddenly, and the plan is individual to you.
What if ruxolitinib does not work either?
There are other options, such as photopheresis, belumosudil for chronic GVHD, other immune-calming medicines or a clinical trial. Your transplant team will review which organs are affected and your counts before suggesting the next step. Ask them to explain why they chose it.
Should I avoid anything while on it?
Avoid people with infections, check with the team before any vaccine, and do not take herbal remedies or grapefruit without asking, since some affect drug levels. Report fever, bleeding, or a painful rash with blisters quickly. Keep taking it at the times your team set.
Can CION help with a second opinion on this decision?
CION's haematology team can review your reports and treatment so far, discuss your case at a tumour board, and help you prepare questions for your transplant centre. CION does not perform transplants, so your transplant team stays responsible for GVHD medicines.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Patient stories
Hear it from people we have treated
Every story is a video, in the patient's own words. Nothing here is a written testimonial.
Sources
- National Cancer Institute — Ruxolitinib Phosphate
- Cancer.Net — Graft-Versus-Host Disease
- Leukemia & Lymphoma Society — Graft-Versus-Host Disease
- National Cancer Institute — Stem Cell Transplants in Cancer Treatment
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Steroids for GVHD and Their Side EffectsThe first treatment, and why it is reduced slowlyAcute vs Chronic GVHDWhy the second-line choice depends on the typeLung GVHD and Bronchiolitis ObliteransA form of chronic GVHD that often needs more than steroidsTargeted therapy guideHow tablet medicines that block cell signals workGraft-versus-Host DiseaseEvery GVHD guide in one place
Talk to us
Want your GVHD treatment plan explained?
Tell us what has been found so far. Our haematology team will review your reports and help you plan the next conversation with your transplant centre.